Figure 5
![Figure 5. Structure of eltrombopag. Eltrombopag [3′-{N′-[1-(3,4-Dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid] has an acidic (COOH) group at one end, lipophilic (CH3) groups at the other end, and a metal chelate group in the center, which create a potent, orally available TPO nonpeptide agonist. Illustration by Paulette Dennis.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/109/11/10.1182_blood-2006-10-019315/4/zh80110703760005.jpeg?Expires=1725020952&Signature=adI5wHIYQYw0PVUg9Gl9Hh5wkqZLbAigKOAqO0U9ZbSrXPyEH5-SpcH0CMkV0SKaFfwwLonf3JiAEbrPMBTJChrC92VM7XyrtFU0BhWx0VwzwI0HX8BbTW3uHXQu7raTjJr1Qo1YkYyFk46CITJ-SC-PCfCnyay8M8LA6c8xU0-g0YzWM2HHTxnXBEC5RLnWmshf-L4BvZT6JGfYpLd5eK~s30Bof2kygMxV~RFWMwM170ksvfVSLjZK8~-a15rQ74b5AvpvO7eLEB~Z0cvRyDXODfehkaO75msT8qBcO~U5OVLzk5ipFo6mPteH66ThyusI3uGkkvAmNHd2ApCdGw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Structure of eltrombopag. Eltrombopag [3′-{N′-[1-(3,4-Dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid] has an acidic (COOH) group at one end, lipophilic (CH3) groups at the other end, and a metal chelate group in the center, which create a potent, orally available TPO nonpeptide agonist. Illustration by Paulette Dennis.
